Haleos Labs Completes Rebrand: New Contact Details and Trading Symbol Live

Haleos Labs Limited has officially implemented its rebranding, updating corporate contact information and its stock trading symbol. This follows the company's formal name change. The new official email addresses are info@haleoslabs.com and cs@haleoslabs.com, with its website now at www.haleoslabs.com. The trading symbol on both the NSE and BSE is now HALEOSLABS, effective November 26, 2025. Operations remain unaffected by these administrative updates.

Key Updates from Filing

Haleos Labs Limited has officially changed its corporate contact details and trading symbol as part of its rebranding.

The company has adopted new official email addresses: info@haleoslabs.com for general inquiries and cs@haleoslabs.com for company secretarial matters.

Its updated official website is now www.haleoslabs.com.

Following the name change, the trading symbol on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) has been updated to HALEOSLABS. This change became effective from November 26, 2025.

Significance of the Changes

This rebranding marks a new corporate identity for the pharmaceutical company. The updated contact information and trading symbol reflect its current branding and operational structure.

These administrative changes are a result of internal decisions and regulatory approvals, including shareholder consent obtained in August 2025.

Company History and Evolution

Haleos Labs Limited has a history of corporate restructuring and name changes. It was originally incorporated as 'Potluri Real Estate Private Limited' in May 2006. Over time, it evolved through names such as 'Potluri Packaging Industries Private Limited' and 'SMS Lifesciences India Private Limited'.

In 2016, it became a wholly-owned subsidiary of SMS Pharmaceuticals Limited before converting to a public limited company. It also underwent a demerger from SMS Pharmaceuticals Limited, with specific semi-regulated business units transferred to SMS Lifesciences, effective April 1, 2016.

The company primarily manufactures Active Pharmaceutical Ingredients (APIs) and intermediates.

Historically, the company has faced regulatory challenges. In fiscal year 2020, a revenue decline was linked to regulatory guidance concerning NDMA impurity in Ranitidine HCL, a key product. However, Haleos Labs (as SMS Lifesciences) has historically focused on semi-regulated markets, which offered some insulation from direct impacts of USFDA bans on certain products.

Impact for Shareholders and Investors

Shareholders and stakeholders should update their records with the new official contact details and be aware of the updated trading symbol.

Investors will now use HALEOSLABS when trading the company's shares on the NSE and BSE.

The company's legal status, Corporate Identification Number (CIN), and day-to-day operational activities remain unaffected by this administrative change.

Regulatory and Market Risks

While the name change is administrative, the company operates in the pharmaceutical API sector, which carries inherent regulatory risks. Haleos Labs has faced regulatory scrutiny and foreign exchange fluctuations in the past.

Product concentration risk has also been a factor, notably seen with Ranitidine HCL in FY20.

Navigating compliance in the global pharmaceutical landscape remains crucial, even for companies serving semi-regulated markets.

Competitive Landscape

Haleos Labs operates within India's significant pharmaceutical sector, competing with major players. Its peers include prominent companies like Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Lupin Ltd., and Dr. Reddy's Laboratories Ltd.

These companies are key manufacturers of APIs, intermediates, and finished formulations, serving both domestic and international markets.

Recent Financials

• The company reported a net profit drop of 17.15% to Rs 497.77 lakhs for Q2 FY2026, with revenue declining by 0.83%.
• For the financial year ending March 31, 2025, Haleos Labs generated revenue of approximately ₹350 crore.

Looking Ahead

Shareholders are advised to ensure their contact records reflect the new email addresses and website for Haleos Labs Limited.

Investors should monitor future communications from the company under its new identity and trading symbol.

The company's future performance will depend on its ability to maintain its market position in API manufacturing and navigate evolving regulatory environments.